Technical Analysis for HOWL - Werewolf Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -1.80% | |
| Stochastic Buy Signal | Bullish | -1.80% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Down 5% | about 21 hours ago |
| Down 3% | about 21 hours ago |
| Down 2 % | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/08/2024
Werewolf Therapeutics, Inc. Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.1939 |
| 52 Week Low | 1.58 |
| Average Volume | 806,586 |
| 200-Day Moving Average | 3.83 |
| 50-Day Moving Average | 2.24 |
| 20-Day Moving Average | 2.30 |
| 10-Day Moving Average | 1.97 |
| Average True Range | 0.22 |
| RSI (14) | 32.43 |
| ADX | 19.4 |
| +DI | 18.58 |
| -DI | 30.80 |
| Chandelier Exit (Long, 3 ATRs) | 3.51 |
| Chandelier Exit (Short, 3 ATRs) | 2.25 |
| Upper Bollinger Bands | 3.16 |
| Lower Bollinger Band | 1.45 |
| Percent B (%b) | 0.11 |
| BandWidth | 74.07 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.08 |
| MACD Histogram | -0.0981 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.77 | ||||
| Resistance 3 (R3) | 1.76 | 1.72 | 1.75 | ||
| Resistance 2 (R2) | 1.72 | 1.68 | 1.72 | 1.74 | |
| Resistance 1 (R1) | 1.68 | 1.66 | 1.66 | 1.68 | 1.73 |
| Pivot Point | 1.63 | 1.63 | 1.62 | 1.63 | 1.63 |
| Support 1 (S1) | 1.59 | 1.60 | 1.57 | 1.60 | 1.55 |
| Support 2 (S2) | 1.55 | 1.58 | 1.55 | 1.54 | |
| Support 3 (S3) | 1.51 | 1.55 | 1.53 | ||
| Support 4 (S4) | 1.51 |
